Intravenous immunoglobulin G is remarkably beneficial in chronic immune dysschwannian/dysneuronal polyneuropathy, diabetes-2 neuropathy, and potentially in severe acute respiratory syndrome

Acta Myologica

Volumn 22, Issue DEC., 2003, Pages 97-103

  Engel, W K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

AUTOIMMUNE DISEASE; CHRONIC DISEASE; CHRONIC IMMUNE DYSSCHWANNIAN; COST OF ILLNESS; DIABETIC NEUROPATHY; DISABILITY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DYSNEURONAL POLYNEUROPATHY; FATALITY; HEADACHE; HOST CELL; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; MIGRAINE; MORBIDITY; MOTOR NERVE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PROTEIN CEREBROSPINAL FLUID LEVEL; RADICULOPATHY; REVIEW; SARS CORONAVIRUS; SENSORY NERVE; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; SUPERINFECTION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; NEURAL CONDUCTION; NEURONS; POLYNEUROPATHIES; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 1542720562     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Engel WK. Rapid and continued improvement from intravenous immunoglobulin treatment of asymmetrical chronic progressive muscular atrophy after 19 years of disease progression. Ann Neurol 1995;38:333-4.
2. Engel WK, Hanna CJ. Intravenous immunoglobulin: Excellent benefit in otherwise refractory progressive muscular atrophy with IgM monoclonal gammopathy. Ann Neurol 1992;32:279.
3. Velazquez L, Engel WK. Chronic relapsing-progressive neuropathy (CRPN) associated with chronic lymphocytic leukemia (CLL): Sustained improvement of neuropathy and CLL from repeated IVIG treatments. Neurology 1994;44:215.
4. Engel WK, Hanna CJ, Misra AK. HTLV-I-associated myelopathy [successfully treated with anti-dysimmune therapy]. New Engl J Med 1990;323:552.
5. Engel WK, Prentice AF. Some polyneuropathies in insulin-requiring adult-onset diabetes can benefit remarkably from anti-dysimmune treatments. Neurology 1993;43:255-6.
6. Engel WK. Polyneuropathy in type-2 diabetes mellitus. The Lancet 2001;358:2086.
7. Engel WK. In type-2 diabetes (D2), diabetic neuropathy and diabeto-2-genetic (D2-Gen) neuropathy are often dysimmune and respond to intravenous IgG (IVIG) treatment. Proc Soc Neurosci, 2001; A 27.
8. Engel WK. Intravenous immunoglobulin. - an often overlooked treatment - produces rapid, remarkable, sustained benefit in diabetic neuropathy complex, suggesting a dysimmune mechanism. Ann Neurol 1997;42:414.
9. Engel WK. In Type-2 Diabetes, Diabetic Neuropathy is usually responsive to Intravenous IgG (IVIG) Treatment, ergo presumably dysimmune. Acta Myol 2002;21:A79.
10. Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002;59:758-65.
11. Krendel, DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52:1053-61.
12. Sharma KR, Cross J, Ayyar DR, et al. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002;59:751-7.
13. Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003;27:465-70.
14. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001;24:1225-8.
15. Sumner CJ, Sheth S, Griffin JW, et al. The Spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60:108-11.
16. Kyle, RA. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993;68:26-36.
17. st edn. Goldman L, Bennett JC, eds. 2000:2197-98.
18. Eaton SEM, Harris ND, Rajbhandari SM, et al. Spinal cord involvement in diabetic peripheral neuropathy. Lancet 2001; 358:35-6.
19. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA 2003;290:1371-6.
20. Mendell, JR. Diabetic neuropathies. In Diagnosis and Management of Peripheral Neuropathies, JR Mendell, JT Kissel, DR Cornblath eds. Oxford Univ. Press, Oxford, UK:2001:373-99.
21. Gominak, S and Parry GJ. Neuropathies and diabetes. In Peripheral Neuropathy, Cros D ed. Lippincott, Williams and Williams, Philadelphia, 2000:109-20.
22. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol 2002;15:595-603.
23. Lavenstein B, Dalakas MC, Engel WK. Polyneuropathy in nonsecretory osteosclerotic multiple myeloma with immunoglobin deposition in peripheral nerve tissue. Neurology 1979;29:611.
24. Dalakas MC, Engel WK. Polyneuropathy with monoclonal gammopathy. Studies of 11 patients. Ann Neurol 1981;10:45-54.
25. Dalakas MC and Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981;9: Suppl 134-145.
26. Sander HW and Latov N. Research criteria for defining patients with CIDP. Neurology 2003;60:S8-S15.
27. Latov N. Diagnosis of CIDP. Neurology 2002;59:S2-S6.
28. Wenzel RP, Edmond, MB. Managing SARS amidst uncertainty. N Engl J Med 2003;348:1947-48.
29. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361:1773-78.
30. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
31. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66.